Advertisement

Topics

APVO Walks The Talk, Eleven Bio Gains Over 13%, PADDOCK Data Boosts APLS

20:59 EDT 16 Apr 2018 | RTTNews

Apellis Pharma gained more than 12%, boosted by interim data from its ongoing phase Ib trial evaluating APL-2 in subcutaneous formulation as a monotherapy in paroxysmal nocturnal hemoglobinuria, dubbed PADDOCK.

Original Article: APVO Walks The Talk, Eleven Bio Gains Over 13%, PADDOCK Data Boosts APLS

NEXT ARTICLE

More From BioPortfolio on "APVO Walks The Talk, Eleven Bio Gains Over 13%, PADDOCK Data Boosts APLS"

Advertisement
Quick Search
Advertisement
Advertisement